CSL112

CSL112 is an investigational intravenous infusion therapy consisting of purified human plasma-derived apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine into disc-shaped high-density lipoprotein (HDL) particles. Developed by CSL for the treatment of acute myocardial infarction (AMI), its primary mechanism is to rapidly enhance cholesterol efflux capacity from macrophages in atherosclerotic plaques via ABCA1-dependent and independent pathways. This process increases pre-beta HDL levels and promotes reverse cholesterol transport to the liver for clearance. In addition to promoting cholesterol efflux, it may exert anti-inflammatory effects that help stabilize vulnerable atherosclerotic plaques during the high-risk period following AMI. Unlike recombinant or mimetic agents, the apoA-I in CSL112 is purified from human plasma[1][3][4][6].

Other names

ApoA-1ApoA1ApoA 1Apolipoprotein A-I - CSL BehringrHDL - CSL